All comparisons

Educational Wellness Information Only

This platform provides peer-reviewed research summaries and educational content about peptides for wellness and optimization purposes. Nothing on this site is intended as medical advice, diagnosis, or treatment. We do not claim any peptide can diagnose, treat, cure, or prevent any disease. Always consult a licensed healthcare provider before beginning any wellness protocol.

Statements on this site have not been evaluated by the FDA. Compounded preparations are subject to applicable state and federal regulations. Availability and eligibility vary.

Clinical comparison

Colistin (Polymyxin E) vs Corticorelin (Acthrel)

An educational, source-based comparison of Colistin (Polymyxin E) and Corticorelin (Acthrel) — how each peptide works, what it's researched for, and what to know before going deeper.

Polymyxin · Infectious Disease
Colistin (Polymyxin E)

Last-resort lipopeptide antibiotic for multidrug-resistant Gram-negatives.

Mechanism

Cationic cyclic lipopeptide that disrupts the outer membrane of Gram-negative bacteria by binding lipid A of LPS, causing membrane permeability and cell death.

Research areas
  • Carbapenem-resistant Acinetobacter, Klebsiella, Pseudomonas
Considerations
  • FDA-approved.
  • Nephrotoxicity and neurotoxicity dose-limiting.
Full Colistin (Polymyxin E) profile →
CRH Analog · Diagnostics
Corticorelin (Acthrel)

Synthetic ovine CRH for differential diagnosis of Cushing's syndrome.

Mechanism

Synthetic ovine corticotropin-releasing hormone (oCRH) that stimulates pituitary ACTH release; used in inferior petrosal sinus sampling and peripheral CRH stimulation testing to distinguish pituitary from ectopic ACTH-dependent Cushing's syndrome.

Research areas
  • Differential diagnosis of ACTH-dependent Cushing's syndrome
Considerations
  • FDA-approved.
  • Transient flushing, dyspnea, hypotension possible.
Full Corticorelin (Acthrel) profile →

Trial-evidence rating

Educational grade reflecting how many peer-reviewed studies and FDA actions we cite for each peptide. Not a clinical recommendation.

Colistin (Polymyxin E)
Strong

FDA-approved with published clinical trial data.

1 cited study
Corticorelin (Acthrel)
Strong

FDA-approved with published clinical trial data.

1 cited study

Study-by-study comparison

PeptideStudySourceYearSummary
Colistin (Polymyxin E)Colistin in MDR Gram-negative infectionsClinical Infectious Diseases2005Effective salvage therapy with manageable nephrotoxicity in modern dosing.
Corticorelin (Acthrel)CRH stimulation and IPSS in Cushing'sJCEM1991Improved discrimination of pituitary vs ectopic ACTH sources.

Side-effect & safety grid

Colistin (Polymyxin E)
  • FDA-approved.
  • Nephrotoxicity and neurotoxicity dose-limiting.
Corticorelin (Acthrel)
  • FDA-approved.
  • Transient flushing, dyspnea, hypotension possible.

Educational summary of considerations reported in research literature — not a complete list of adverse events. Discuss with a licensed clinician before any use.

Colistin (Polymyxin E) vs Corticorelin (Acthrel) — Key differences

  • Class: Colistin (Polymyxin E) is classified as Polymyxin · Infectious Disease, while Corticorelin (Acthrel) is CRH Analog · Diagnostics.
  • Primary research focus: Colistin (Polymyxin E)carbapenem-resistant acinetobacter, klebsiella, pseudomonas; Corticorelin (Acthrel)differential diagnosis of acth-dependent cushing's syndrome.
  • Tag: FDA-Approved · Antibiotic vs FDA-Approved · Diagnostics.

Related comparisons